Results 21 to 30 of about 29,392 (188)

Plasma apixaban levels in Chinese patients with chronic kidney disease—Relationship with renal function and bleeding complications

Frontiers in Pharmacology, 2022
Introduction: Accumulation of apixaban in plasma is a major concern in patients with chronic kidney disease (CKD). Studies that investigated plasma apixaban level in CKD patients and its association with clinically significant events are scarce.Methods ...
Chun-fung Sin, Ka-ping Wong, Ka-ping Wong, Tsz-fu Wong, Chung-wah Siu, Desmond Y. H. Yap   +5 more
doaj   +1 more source

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study

CPT: Pharmacometrics & Systems Pharmacology, 2023
This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real‐world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model‐based simulations helped to identify factors that affect apixaban
Frédéric Gaspar, Jean Terrier, Samantha Favre, Pauline Gosselin, Pierre Fontana, Youssef Daali, Camille Lenoir, Caroline Flora Samer, Victoria Rollason, Jean‐Luc Reny, Chantal Csajka, Monia Guidi   +11 more
doaj   +1 more source

Reversible Neurological Adverse Reaction to Apixaban [PDF]

, 2021
Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins ...
Vicente, Leopoldina, Rodrigues Cernadas, Eduardo, Estevão, Dália, Dionisio, Catarina, null Catarina Dionisio, Dalia Estevão, null Leopoldina Vicente, Leopoldina Vicente, Catarina Dionisio, null Eduardo Rodrigues Cernadas, Eduardo Rodrigues Cernadas, null Dalia Estevão   +11 more
core   +1 more source

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

Journal of Arrhythmia, 2017
Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual
Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita   +9 more
doaj   +1 more source

Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation.

PLoS ONE
BackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen, Sarawuth Limprasert, Pornwalai Boonmuang, Manat Pongchaidecha, Juthathip Suphanklang, Weerayuth Saelim, Wichai Santimaleeworagun, Piyarat Pimsi   +7 more
doaj   +1 more source

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

Research and Practice in Thrombosis and Haemostasis, 2021
Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which ...
Verónica Bravo Villa, Job Romero, Eunice Rojas‐Zaldivar, Martha Cervantes, María del Rosario Villa‐Márquez, Patricia Baz, Gabriela Cesarman‐Maus   +6 more
doaj   +1 more source

Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series

Annals of Saudi Medicine
BACKGROUND: Apixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE).
Hakeam A. Hakeam, Sandra McGrath, Ghader Alrebeh, Abdullah F. Alrebdi   +3 more
doaj   +1 more source

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation [PDF]

, 2019
Aims Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome.
Gorog, Diana A., Arachchillage, Deepa RJ, Spinthakis, Nikolaos, Gue, Ying X., Lip, Gregory YH, Arachchillage, Deepa R.J., Wellsted, David, Gue, Ying, Farag, Mohamed, Lip, Gregory Y.H., Gorog, Diana A, Srinivasan, Manivannan, Lip, Gregory Y H, Gorog, Diana   +13 more
core   +1 more source

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy

Hitit Medical Journal, 2020
An 80-year-old female was admitted to the hospital, presenting a pulsatile and painless mass on the right temporal site occurred one month ago following a blunt head trauma.
Sertan Özyalçın, Adem İlkay Diken, Adnan Yalçınkaya, Ufuk Türkmen   +3 more
doaj  

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration

Frontiers in Veterinary Science, 2018
Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while ...
Priscila B. S. Serpa, Marjory B. Brooks, Thomas Divers, Sally Ness, Ingvild Birschmann, Mark G. Papich, Tracy Stokol   +6 more
doaj   +1 more source